Wugen Announces CEO Transition

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 25, 2024

Ouro Teams Up with Texas One Fund with Multi-Year NIL X World Wallet Financial Empowerment Program for University of Texas Stude • Leading Industry Publication: Black & Veatch Remains Among Global Critical Infrastructure Leaders as Sustainability, Decarbo • Bay Square at Yarmouth Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Third Strai • CUPE BC, province’s largest union, kicks off convention in Vancouver • ERVIN COHEN & JESSUP PARTNER RECOGNIZED AS TOP LAWYER IN LOS ANGELES • God's Mighty Hand Can Uphold His Children Even Through The Hardest Times • Wounded Warrior Project, White House Celebrate and Honor Warriors at Annual Soldier Ride • Motlow State Community College Expands Accessibility With the Addition of YuJa Panorama Digital Accessibility Platform to Its Ed • WM Announces First Quarter 2024 Earnings • NICOLE ARI PARKER IS THE FACE OF KAREN MILLEN'S ICONS SERIES VOL. 6 • Orion S.A. Earns Platinum Sustainability Rating by EcoVadis • The Birches at Concord Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Third Strai • Bureau Veritas: Strong Start to the Year; 2024 Outlook Confirmed • ACTS LAW Addresses Federal Correctional Institution in Dublin Controversy • Asahi Kasei to Construct a Lithium-ion Battery Separator Plant in Canada • White House Correspondents’ Association Dinner to Welcome Hooman Shahidi, Co-founder and CEO of EVPassport, the Rapidly Gr • PONIX AWARDED $5 MILLION USDA GRANT TO BREAK "GROUND" ON CLIMATE-SMART AGRICULTURE IN GEORGIA • Benchmark Senior Living at Hamden Assisted Living Community Named One of the Country's Best by U.S. News & World Report • Walgreens Launches Gene and Cell Services as Part of Newly Integrated Walgreens Specialty Pharmacy Business • Voices for Humanity Bears Witness to Panama's Moral Resurgence With Giselle Lima

Wugen Announces CEO Transition

ST. LOUIS & SAN DIEGO , March 21 /Businesswire/ - Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that Kumar Srinivasan Ph.D., M.B.A., has been appointed President and Chief Executive Officer, effective March 13, 2023. Dr. Srinivasan succeeds Dan Kemp, Ph.D., who has stepped down from his CEO role and the Board of Directors to pursue other opportunities.

“We are delighted to welcome Kumar as Wugen’s next CEO and look forward to leveraging his global leadership, deep expertise in the biopharmaceutical industry, and strong track record of success in company building, corporate strategy, and business development. Under his leadership, the company will be well-positioned to advance our differentiated platform of memory NK and allogeneic CAR-T therapies for patients,” said Natalie Mount, Ph.D., Chair of the Board of Directors at Wugen. “We’d like to thank Dan for his leadership and contributions to the company over the past two years and wish him the best of luck in his future endeavors.”

“I am thrilled to be joining Wugen at this exciting time for the company,” said Dr. Srinivasan. “Wugen has made incredible strides advancing treatments for cancer patients. I look forward to working with Wugen’s talented team as CEO and to continue to execute on our lead clinical-assets, WU-NK-101 and WU-CART-007. Wugen’s memory NK and allogeneic CAR-T cell therapies have the potential to improve patient outcomes by helping to address the needs of patients with solid tumors, acute myeloid leukemia (AML), and T-cell malignancies."

Dr. Srinivasan has over 25 years of experience leading pharmaceutical and biotechnology companies through critical stages of growth, M&A activity, and new product launches. Most recently, he served as executive vice president and chief business officer at Turning Point Therapeutics. Under his leadership, Dr. Srinivasan successfully executed a partnering strategy for reprotrectinib that ultimately led to the acquisition of the company by Bristol Myers Squibb. Before Turning Point Therapeutics, Dr. Srinivasan was vice president and global head of business development for the BioPharmaceuticals business unit at AstraZeneca, where he was instrumental in leading several in-licensing deals that significantly enhanced the strength of the company’s pipeline, established several high priority collaborations, and led all global and regional COVID-19 related business development efforts. Earlier in his career, he held corporate strategy and business development roles at Probiodrug AG, Wyeth Pharmaceuticals, and TorreyPines Therapeutics. Dr. Srinivasan holds an M.B.A. from the University of Chicago, a Ph.D. in organic chemistry from Case Western Reserve University, and a dual B.S./M.S. in chemistry from the University of Madras.

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta™ platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit www.wugen.com.